Pfizer Abandoning Indiplon Deal; Neurocrine Falls Again
A week after reporting that additional trials likely would be necessary for approval of its sleep drug, indiplon, Neurocrine Biosciences Inc. suffered another blow with the loss of its commercialization partner, Pfizer Inc. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.